Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Common Share	6 Months Ended
Net Income (Loss) Per Common Share	Jun. 30, 2017
Net Income (Loss) Per Common Share [Abstract]
Net Income (Loss) Per Common Share	9.Net Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding, plus the number of common share equivalents that would be dilutive. As of June 30, 2017 and December 31, 2016, there were stock options, restricted stock units and warrants to acquire, in the aggregate, 7,280,637 and 7,142,728 shares of the Company’s common stock, respectively, that are potentially dilutive. However, with the exception of the three months ended June 30, 2017, diluted loss per share is the same as basic loss per share for all periods presented because the inclusion of common share equivalents would be anti-dilutive. For the three months ended June 30, 2017, the dilutive effect of stock warrants, stock options and restricted stock units is 1,177,987, 1,031,356 and 54,300, respectively.